Embryonal sarcoma of the liver in pediatric and young adult patients: A report from Children's Oncology Group study ARST0332

Sheri L. Spunt,Wei Xue,Zhengya Gao,Andrea Hayes Dixon,Lynn Million,Stephanie F. Polites,Sanjeev A. Vasudevan,Simon C. Kao,M. Beth McCarville,David M. Parham,Donald A. Barkauskas,Zhongjie Cai,Carrye Cost,Leo Mascarenhas,Aaron R. Weiss
DOI: https://doi.org/10.1002/cncr.35305
IF: 6.9209
2024-04-04
Cancer
Abstract:Background Embryonal sarcoma of the liver (ESL) is a rare mesenchymal tumor most common in childhood; the optimal treatment approach is uncertain. The clinical features and outcomes of patients with ESL enrolled in a Children's Oncology Group (COG) clinical trial that evaluated a risk‐based strategy for treating soft tissue sarcomas in patients aged 10 cm in diameter; four were metastatic. Tumor resection was performed upfront in 23 and delayed in 16. Positive surgical margins (n = 6) and intraoperative tumor rupture (n = 6) occurred only in upfront resections. Eight patients received radiotherapy. Estimated 5‐year event‐free and overall survival were 79% (95% confidence interval [CI], 65%–93%) and 95% (95% CI, 87%–100%), respectively. Positive margins increased the local recurrence risk. One of 13 patients with documented hemorrhagic ascites and/or tumor rupture developed extrahepatic intra‐abdominal tumor recurrence. Conclusions The treatment strategy used in ARST0332 achieved favorable outcomes for patients with ESL despite a substantial proportion having high‐risk disease features. Deferring tumor resection until after neoadjuvant chemotherapy may decrease the risk of intraoperative tumor rupture and improve the likelihood of adequate surgical margins.
oncology
What problem does this paper attempt to address?